VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totaling 14,885 shares, a decrease of 54.7% from the February 26th total of 32,826 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average trading volume of 60,908 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 8.23% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, VivoSim Labs presently has a consensus rating of “Sell”.

VivoSim Labs Trading Down 0.1%

NASDAQ VIVS traded down $0.00 on Thursday, hitting $1.70. 2,311 shares of the company were exchanged, compared to its average volume of 1,746,975. The company has a market cap of $4.43 million, a PE ratio of -0.54 and a beta of 1.25. The stock has a fifty day moving average of $1.98 and a 200-day moving average of $2.35. VivoSim Labs has a 12 month low of $1.41 and a 12 month high of $5.30.

VivoSim Labs (NASDAQ:VIVS) last posted its quarterly earnings results on Wednesday, February 11th. The company reported ($1.03) earnings per share for the quarter. The company had revenue of $0.03 million during the quarter. VivoSim Labs had a negative net margin of 861.27% and a negative return on equity of 15.51%.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.